Cargando…

Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?

Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability...

Descripción completa

Detalles Bibliográficos
Autores principales: do Carmo Silva, Lívia, de Oliveira, Amanda Alves, de Souza, Dienny Rodrigues, Barbosa, Katheryne Lohany Barros, Freitas e Silva, Kleber Santiago, Carvalho Júnior, Marcos Antonio Batista, Rocha, Olívia Basso, Lima, Raisa Melo, Santos, Thaynara Gonzaga, Soares, Célia Maria de Almeida, Pereira, Maristela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712482/
https://www.ncbi.nlm.nih.gov/pubmed/33228010
http://dx.doi.org/10.3390/jof6040300
_version_ 1783618383844999168
author do Carmo Silva, Lívia
de Oliveira, Amanda Alves
de Souza, Dienny Rodrigues
Barbosa, Katheryne Lohany Barros
Freitas e Silva, Kleber Santiago
Carvalho Júnior, Marcos Antonio Batista
Rocha, Olívia Basso
Lima, Raisa Melo
Santos, Thaynara Gonzaga
Soares, Célia Maria de Almeida
Pereira, Maristela
author_facet do Carmo Silva, Lívia
de Oliveira, Amanda Alves
de Souza, Dienny Rodrigues
Barbosa, Katheryne Lohany Barros
Freitas e Silva, Kleber Santiago
Carvalho Júnior, Marcos Antonio Batista
Rocha, Olívia Basso
Lima, Raisa Melo
Santos, Thaynara Gonzaga
Soares, Célia Maria de Almeida
Pereira, Maristela
author_sort do Carmo Silva, Lívia
collection PubMed
description Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the research and development of new molecules. Researchers have concentrated efforts on the identification of new compounds using numerous tools and targeting important proteins from Paracoccidioides, with the emphasis on enzymatic pathways absent in humans. This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM.
format Online
Article
Text
id pubmed-7712482
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77124822020-12-04 Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? do Carmo Silva, Lívia de Oliveira, Amanda Alves de Souza, Dienny Rodrigues Barbosa, Katheryne Lohany Barros Freitas e Silva, Kleber Santiago Carvalho Júnior, Marcos Antonio Batista Rocha, Olívia Basso Lima, Raisa Melo Santos, Thaynara Gonzaga Soares, Célia Maria de Almeida Pereira, Maristela J Fungi (Basel) Review Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the research and development of new molecules. Researchers have concentrated efforts on the identification of new compounds using numerous tools and targeting important proteins from Paracoccidioides, with the emphasis on enzymatic pathways absent in humans. This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM. MDPI 2020-11-19 /pmc/articles/PMC7712482/ /pubmed/33228010 http://dx.doi.org/10.3390/jof6040300 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
do Carmo Silva, Lívia
de Oliveira, Amanda Alves
de Souza, Dienny Rodrigues
Barbosa, Katheryne Lohany Barros
Freitas e Silva, Kleber Santiago
Carvalho Júnior, Marcos Antonio Batista
Rocha, Olívia Basso
Lima, Raisa Melo
Santos, Thaynara Gonzaga
Soares, Célia Maria de Almeida
Pereira, Maristela
Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
title Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
title_full Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
title_fullStr Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
title_full_unstemmed Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
title_short Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
title_sort overview of antifungal drugs against paracoccidioidomycosis: how do we start, where are we, and where are we going?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712482/
https://www.ncbi.nlm.nih.gov/pubmed/33228010
http://dx.doi.org/10.3390/jof6040300
work_keys_str_mv AT docarmosilvalivia overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT deoliveiraamandaalves overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT desouzadiennyrodrigues overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT barbosakatherynelohanybarros overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT freitasesilvaklebersantiago overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT carvalhojuniormarcosantoniobatista overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT rochaoliviabasso overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT limaraisamelo overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT santosthaynaragonzaga overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT soaresceliamariadealmeida overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing
AT pereiramaristela overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing